Compare Northrop Grumman Corporation (NOC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs TransMedics Group Inc — how do they compare? Northrop Grumman Corporation trades at $578.18 (market cap $81.78B), while TransMedics Group Inc trades at $87.43 (market cap $3.10B). The key difference: Northrop Grumman Corporation is far larger — about 26.4× TransMedics Group Inc's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NOC | TMDX | |
|---|---|---|
Market Cap | $81.78B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $768.02 | $150.42 |
52-Week Low | $496.02 | $61.99 |
Enterprise Value | $95.77B | $3.49B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $577.12, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $7.68, and raised full-year guidance, supported by a record $105 billion backlog. Revenue growth is steady, with 2026 projected at $42.9 billion, and profitability remains solid with a net income margin of 10.48%.
The outlook is positive, driven by strategic contracts like the $7.6 billion Sentinel program and defense spending tailwinds. Risks include margin pressures from specific programs and geopolitical uncertainties. Analysts are bullish with a consensus price target of $598.57, suggesting upside potential from current levels.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
